PROCTOFOAM HC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROCTOFOAM HC (PROCTOFOAM HC).
Hydrocortisone is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by binding to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression, leading to suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes) and inhibition of immune cell migration. Pramoxine is a local anesthetic that reversibly blocks sodium ion channels in nerve membranes, thereby inhibiting initiation and conduction of sensory nerve impulses.
| Metabolism | Hydrocortisone is metabolized primarily in the liver via reduction and conjugation, followed by renal excretion. Pramoxine undergoes hepatic metabolism via glucuronidation and sulfation. |
| Excretion | Hydrocortisone is metabolized in the liver, primarily to inactive metabolites (tetrahydrocortisone and tetrahydrocortisol). Less than 1% of the dose is excreted unchanged in urine. Fecal excretion is negligible. |
| Half-life | The terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours. After topical application to the rectal mucosa, systemic absorption is minimal, resulting in a half-life comparable to that of endogenous cortisol, with clinical effects lasting about 6-8 hours. |
| Protein binding | Hydrocortisone is highly protein-bound (90-95%), primarily to corticosteroid-binding globulin (CBG, also known as transcortin) and to a lesser extent to albumin. |
| Volume of Distribution | The volume of distribution of hydrocortisone is approximately 0.5-1.0 L/kg, reflecting distribution into total body water. Due to minimal systemic absorption after rectal administration, the Vd is not clinically relevant for local therapy. |
| Bioavailability | Rectal administration: Systemic bioavailability is approximately 1-5% due to extensive first-pass metabolism in the liver and limited absorption. Most of the drug acts locally with minimal systemic exposure. |
| Onset of Action | Rectal administration: Onset of anti-inflammatory action is typically within 1-2 hours, with symptomatic relief (reduction of itching, pain, and inflammation) observed within 2-4 hours. |
| Duration of Action | Rectal application: Duration of action is approximately 6-8 hours, consistent with the dosing interval of twice daily. Note: The foam allows prolonged contact with the rectal mucosa, enhancing local efficacy. |
Rectal aerosol foam: 1 applicatorful (6.5% pramoxine HCl / 1% hydrocortisone) rectally 2-3 times daily. Maximum 4 weeks.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dose adjustment needed. Systemic absorption minimal. |
| Liver impairment | No dose adjustment needed. Topical use with minimal systemic absorption. |
| Pediatric use | Not recommended in children under 12 years. For ages ≥12: same as adult dosing. |
| Geriatric use | No specific dose adjustment; apply caution due to potential skin atrophy in elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROCTOFOAM HC (PROCTOFOAM HC).
| Breastfeeding | Systemic corticosteroids appear in breast milk in low amounts. Topical/rectal use results in negligible systemic absorption, unlikely to cause effects in nursing infant. M/P ratio not established for this formulation. Caution with prolonged application to large areas. Generally considered compatible with breastfeeding. |
| Teratogenic Risk | Hydrocortisone acetate, the active ingredient, is a corticosteroid. Topical and rectal administration results in minimal systemic absorption. Animal studies with corticosteroids have shown teratogenicity, but adequate human studies in pregnancy are lacking. First trimester: Risk cannot be ruled out; use only if clearly needed. Second/Third trimester: No known specific risks; avoid prolonged use. Overall FDA Pregnancy Category C. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to hydrocortisone, pramoxine, or any component of the formulation. Fungal, viral, or bacterial infections at the application site. Premature infants (due to benzyl alcohol content in some formulations).
| Precautions | Topical corticosteroids may cause systemic absorption, especially with prolonged use or application to large areas, leading to hypothalamic-pituitary-adrenal (HPA) axis suppression. Reversible HPA axis suppression may occur after discontinuation. Use with caution in patients with impaired skin integrity. Avoid use in eyes. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required unless used chronically in high doses. In such cases, monitor maternal blood pressure, blood glucose, and signs of infection. Fetal growth monitoring not routinely indicated. |
| Fertility Effects | No known effects on fertility from topical/rectal hydrocortisone. Systemic corticosteroids may affect ovulation; negligible systemic absorption with this formulation makes fertility impact unlikely. |